Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana – ANA Abstract Submission NLP

October 17, 2016August 16, 2022 Alterity Therapeutics

final-ana-abstract-submission-nlp-4-8-16

2016

Post navigation

New data from Reach2HD trial presented at American Neurological Association Annual Meeting

Related Posts

Alterity receives a $4.8 million R&D Tax Incentive Refund

January 15, 2020August 16, 2022

Prana receives $3 million R&D Tax Incentive Refund

December 19, 2017August 16, 2022

Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial

February 16, 2023May 23, 2023

Recent Posts

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting
AGM 2024 Presentation
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065